Wyrick Susan D. 4

What Happened Susan D. Wyrick, Senior Vice President, Finance and Accounting and Principal Accounting Officer at Sana Biotechnology (SANA), was awarded two equity grants on 2026-03-05: 206,250 restricted stock units (RSUs) and 45,833 stock option-type awards. Both grants were reported as derivative awards at $0.00 per share (no cash paid). Together these awards represent the contingent right to receive up to 252,083 shares of SANA common stock if vesting conditions are met.

Key Details

• Transaction date: 2026-03-05; Form 4 filed 2026-03-06 (timely filing).
• Award amounts: 206,250 RSUs and 45,833 option-style awards; reported price $0.00 (grant/award).
• Vesting: RSUs vest in four equal installments on March 5 of 2027, 2028, 2029 and 2030; the option-style award vests 25% on March 5, 2027 and then in 36 equal monthly installments thereafter (contingent on continued service).
• Shares owned after transaction: not specified in the provided excerpt.
• Filing remarks: reported role — SVP, Finance and Accounting and Principal Accounting Officer.
• No indication of a 10b5-1 plan, sale, purchase, tax withholding or cashless exercise in the provided filing excerpt.

Context

• RSUs are contingent rights to receive shares upon vesting; they are compensation, not an immediate stock purchase or sale.
• The option-style award vests over time and must typically be exercised (if applicable) before any shares are received; nothing in this filing indicates any immediate sale of shares.
• Such grants are routine for executive compensation and do not by themselves indicate a buy or sell market signal; they reflect future potential dilution if vested and settled.